Market Overview:
The global cancer testing/screening market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, growing awareness about cancer screening, and technological advancements in the field of cancer testing/screening. The global cancer testing/screening market by type is segmented into magnetic resonance imaging (MRI), human papillomavirus (HPV) testing, colonoscopy, and others. The MRI segment accounted for the largest share of the global cancer testing/screening market in 2017 and is projected to grow at a CAGR of 7.8% from 2018 to 2030. This growth can be attributed to the increasing demand for MRI as a diagnostic tool for various types of cancers and its ability to provide high-resolution images that help in accurate diagnosis.
Product Definition:
Cancer testing/screening is the process of checking for cancer in people who do not have any symptoms. Cancer testing/screening can help find cancer early, when it is more likely to be cured.
Magnetic Resonance Imaging (MRI):
Magnetic resonance imaging (MRI) is an advanced diagnostic medical technology that uses magnetic fields and radio waves to produce images of body tissues without the use of ionizing radiation. MRI works by causing hydrogen nuclei to line up in the presence of a strong magnetic field, which causes them to absorb energy from the field and flip around, creating a signal.
Human Papillomavirus (HPV) Testing:
Human papillomavirus (HPV) testing and its usage in cancer screening market is expected to grow at a significant rate during the forecast period. The presence of government organizations such as the U.S. FDA, WHO, CDC & EMA along with various non-profit organizations involved in supporting research activities related to oncology is one of the key factors driving growth of this market globally.
Application Insights:
The lung cancer segment dominated the market in 2017 and is expected to continue its dominance over the forecast period. This can be attributed to factors such as availability of advanced treatment options, rising prevalence of smoking and high demand for early diagnosis methods. For instance, according to a study published by NCBI in 2018, around 54% of all lung cancer cases are caused by tobacco use worldwide.
In addition, growing awareness about early detection among individuals at risk is also expected to drive growth during the forecast period. An increasing number of government initiatives promoting regular screening will also have a positive impact on market growth during the forecast period.
Regional Analysis:
North America dominated the global cancer testing/screening market in 2017. This can be attributed to the presence of key players, high adoption rate of advanced technologies, and availability of well-developed healthcare infrastructure. Moreover, rising prevalence of cancer is also expected to contribute towards growth during the forecast period. Asia Pacific is estimated to witness lucrative growth over the coming years owing to increasing government initiatives for early diagnosis and treatment as well as growing awareness about available screening programs among population at large. In addition, improving healthcare infrastructure in this region will also help boost market development during the forecast period.
The industry has been segmented into four major categories namely product launch; approvals; product launches in countries outside Japan; and new products/condoms etc based on disease prevention measures (DPM).
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the rising prevalence of lifestyle-related risk factors such as smoking, obesity, and alcohol consumption. According to a study by the World Health Organization (WHO), the number of new cancer cases is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a large demand for cancer testing and screening services.
- Advances in technology: The field of oncology is rapidly evolving, with new technologies being developed for early detection and treatment of cancer. For instance, next-generation sequencing (NGS) has revolutionized tumor profiling, making it possible to identify genetic mutations associated with specific cancers within minutes instead of weeks or months. Such advances are likely to spur growth in the market for cancer testing and screening services over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Testing/Screening Market Research Report
By Type
Magnetic Resonance Imaging (MRI), Human Papillomavirus (HPV) Testing, Colonoscopy, Others
By Application
Lung Cancer, Blood Cancer, Bone Cancer, Gall Bladder Cancer, Others
By Companies
Dias Orin, Epigenetics, Techlab, Positive Bioscience, Genextropy, M Genomics, 20/20 GeneSystems, AB SCIEX, Abbott Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
228
Number of Tables & Figures
160
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Testing/Screening Market Report Segments:
The global Cancer Testing/Screening market is segmented on the basis of:
Types
Magnetic Resonance Imaging (MRI), Human Papillomavirus (HPV) Testing, Colonoscopy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Blood Cancer, Bone Cancer, Gall Bladder Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dias Orin
- Epigenetics
- Techlab
- Positive Bioscience
- Genextropy
- M Genomics
- 20/20 GeneSystems
- AB SCIEX
- Abbott Laboratories
Highlights of The Cancer Testing/Screening Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Magnetic Resonance Imaging (MRI)
- Human Papillomavirus (HPV) Testing
- Colonoscopy
- Others
- By Application:
- Lung Cancer
- Blood Cancer
- Bone Cancer
- Gall Bladder Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Testing/Screening Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer testing and screening is the process of detecting cancer in people who may be at risk for the disease. Cancer screening tests can include blood tests, mammograms, and prostate exams.
Some of the major companies in the cancer testing/screening market are Dias Orin, Epigenetics, Techlab, Positive Bioscience, Genextropy, M Genomics, 20/20 GeneSystems, AB SCIEX, Abbott Laboratories.
The cancer testing/screening market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Testing/Screening Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Testing/Screening Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Testing/Screening Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Testing/Screening Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Testing/Screening Market Size & Forecast, 2018-2028
4.5.1 Cancer Testing/Screening Market Size and Y-o-Y Growth
4.5.2 Cancer Testing/Screening Market Absolute $ Opportunity
Chapter 5 Global Cancer Testing/Screening Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer Testing/Screening Market Size Forecast by Type
5.2.1 Magnetic Resonance Imaging (MRI)
5.2.2 Human Papillomavirus (HPV) Testing
5.2.3 Colonoscopy
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer Testing/Screening Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer Testing/Screening Market Size Forecast by Applications
6.2.1 Lung Cancer
6.2.2 Blood Cancer
6.2.3 Bone Cancer
6.2.4 Gall Bladder Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Testing/Screening Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Testing/Screening Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer Testing/Screening Analysis and Forecast
9.1 Introduction
9.2 North America Cancer Testing/Screening Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer Testing/Screening Market Size Forecast by Type
9.6.1 Magnetic Resonance Imaging (MRI)
9.6.2 Human Papillomavirus (HPV) Testing
9.6.3 Colonoscopy
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer Testing/Screening Market Size Forecast by Applications
9.10.1 Lung Cancer
9.10.2 Blood Cancer
9.10.3 Bone Cancer
9.10.4 Gall Bladder Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer Testing/Screening Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer Testing/Screening Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer Testing/Screening Market Size Forecast by Type
10.6.1 Magnetic Resonance Imaging (MRI)
10.6.2 Human Papillomavirus (HPV) Testing
10.6.3 Colonoscopy
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer Testing/Screening Market Size Forecast by Applications
10.10.1 Lung Cancer
10.10.2 Blood Cancer
10.10.3 Bone Cancer
10.10.4 Gall Bladder Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer Testing/Screening Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer Testing/Screening Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer Testing/Screening Market Size Forecast by Type
11.6.1 Magnetic Resonance Imaging (MRI)
11.6.2 Human Papillomavirus (HPV) Testing
11.6.3 Colonoscopy
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer Testing/Screening Market Size Forecast by Applications
11.10.1 Lung Cancer
11.10.2 Blood Cancer
11.10.3 Bone Cancer
11.10.4 Gall Bladder Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer Testing/Screening Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer Testing/Screening Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer Testing/Screening Market Size Forecast by Type
12.6.1 Magnetic Resonance Imaging (MRI)
12.6.2 Human Papillomavirus (HPV) Testing
12.6.3 Colonoscopy
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer Testing/Screening Market Size Forecast by Applications
12.10.1 Lung Cancer
12.10.2 Blood Cancer
12.10.3 Bone Cancer
12.10.4 Gall Bladder Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer Testing/Screening Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer Testing/Screening Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer Testing/Screening Market Size Forecast by Type
13.6.1 Magnetic Resonance Imaging (MRI)
13.6.2 Human Papillomavirus (HPV) Testing
13.6.3 Colonoscopy
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer Testing/Screening Market Size Forecast by Applications
13.10.1 Lung Cancer
13.10.2 Blood Cancer
13.10.3 Bone Cancer
13.10.4 Gall Bladder Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Testing/Screening Market: Competitive Dashboard
14.2 Global Cancer Testing/Screening Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dias Orin
14.3.2 Epigenetics
14.3.3 Techlab
14.3.4 Positive Bioscience
14.3.5 Genextropy
14.3.6 M Genomics
14.3.7 20/20 GeneSystems
14.3.8 AB SCIEX
14.3.9 Abbott Laboratories
